CTU1 Inhibitors
CTU1 Inhibitors are a diverse set of compounds that interfere with various cellular components and pathways, ultimately leading to the inhibition of the functional activity of CTU1. Several of these inhibitors target the cytoskeletal network, which plays a critical role in the proper localization and transport of CTU1 within the cell. For example, colchicine disrupts microtubule polymerization, and paclitaxel hyperstabilizes microtubules, both of which can impede the intracellular trafficking and the functional deployment of CTU1. Similarly, inhibitors like Blebbistatin, Y-27632, NSC 23766, and ML-7 disrupt the actin cytoskeleton dynamics by targeting myosin II, ROCK, Rac1, and MLCK, respectively. These alterations can affect the cellular processes necessary for CTU1's activity, such as its movement to specific subcellular locales or its interactions with other proteins.
Additionally, CTU1 inhibitorsinclude compounds that interfere with signaling pathways potentially linked to the activity of CTU1. Inhibitors like PD 98059 and U73122 target the MAPK/ERK pathway and phospholipase C, respectively, which could lead to the modulation of pathways that CTU1 might depend on for its function. PI3K inhibitors such as Wortmannin and LY294002 disrupt downstream signaling responsible for a variety of cellular processes, and if CTU1 is part of these processes, its function would be indirectly diminished. Similarly, compounds like SB 203580 and SP600125 inhibit p38 MAP kinase and JNK, respectively, which might tie into stress response mechanisms or other pathways relevant to CTU1's functional activity. By inhibiting these kinases, the compounds could disrupt the signaling cascades that facilitate CTU1's role in the cell, leading to an inhibitory effect on its activity.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $100.00 $321.00 $2289.00 $4484.00 $18207.00 $34749.00 | 3 | |
Colchicine binds to tubulin, preventing its polymerization into microtubules and disrupting microtubule dynamics. Since CTU1 is involved in cytoskeleton-related processes, the disruption of microtubules by colchicine can impede the intracellular trafficking necessary for CTU1 activity. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Paclitaxel stabilizes microtubules and prevents their disassembly, which can paradoxically disrupt microtubule dynamics as much as depolymerization. This stabilization can interfere with the proper distribution of CTU1 within the cell, indirectly inhibiting its function. | ||||||
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $72.00 $265.00 $495.00 $968.00 | ||
Blebbistatin inhibits myosin II ATPase activity, affecting actin-myosin interactions and thus actin filament dynamics. The alteration of actin filaments can affect the cellular localization and function of CTU1 by disrupting the actin-based transport mechanisms. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 inhibits the Rho-associated protein kinase (ROCK), which is involved in actin cytoskeleton organization. By inhibiting ROCK, Y-27632 may alter the actin cytoskeletal structure necessary for CTU1's proper cellular localization and function. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
NSC 23766 inhibits the activation of Rac1, which is a GTPase that regulates actin cytoskeleton organization. The inhibition of Rac1 can disrupt cellular processes that depend on actin dynamics, potentially impairing CTU1's function. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML-7 is an inhibitor of myosin light chain kinase (MLCK), which phosphorylates myosin light chains to promote actin-myosin interactions. By inhibiting MLCK, ML-7 can alter actin cytoskeleton dynamics, thus affecting CTU1's activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 inhibits MEK, which is part of the MAPK/ERK pathway. Since CTU1 may rely on signaling through this pathway for proper function, inhibiting MEK can indirectly impede CTU1's activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor, which prevents the phosphorylation and activation of downstream targets involved in cell survival and growth. As CTU1 may interact with PI3K signaling pathways, wortmannin can indirectly inhibit CTU1 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor that prevents the phosphorylation of AKT, thereby affecting cell survival and growth pathways. This inhibition can decrease CTU1's activity by disrupting signaling mechanisms it is involved in. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 inhibits p38 MAP kinase, affecting inflammatory response and stress-induced cellular pathways. By inhibiting p38, it can indirectly inhibit CTU1 activity if CTU1 is involved in these stress response pathways. | ||||||